In contrast to its role in central tolerance (nonresponsiveness toward abundantly expressed self antigens), the contribution of the thymus to peripheral tolerance (tolerance to self antigens that are only minimally expressed and/or are expressed by only one or a few organs) is not well understood. Thus the long-term objective of the proposed research is to determine if reduction or loss of intrathymic expression of self antigens contributes to failure of peripheral tolerance and induction of autoimmune disease. As an initial step towards this objective we will focus our efforts on a unique animal model, i.e. Iupus-prone BW mice that express a human C- reactive protein (CRP) transgene as a neo-self antigen. Despite recent reports that CRP-transgenic (CRPtg) mice tolerate human CRP due to thymic expression of the transgene, aged CRPtg/BW mice express high titers of serum anti-human CRP autoantibodies. This mimics the situation seen in patients with SLE. We hypothesize that in BW mice the loss of tolerance to CRP and other 'organ-specific' peripheral antigens is accelerated due to compromised thymic expression. To test this hypothesis we will focus our efforts on three specific aims. 1) We will determine the time-course of thymic expression of peripheral autoantigens in autoimmune versus normal mice. Thymic expression of the candidate autoantigens CRP, myelin basic protein (MBP), Fas ligand (FasL), and thyroglobulin will be quantitated for female mice of various ages. Thymic expression in autoimmune CRPtg/BW versus nonautoimmune CRPtg strains (CRPtg/NZW and CRPtg/B6) will be compared. 2) We will determine if intra and extrathymic expression of peripheral autoantigens are differentially regulated. Constitutive and induced hepatic versus thymic expression of CRP and serum amyloid P-component will be compared for CRPtg BW, NZW, and B6 mice. Endotoxin, IL-6, and testosterone will be used for inductions. 3) We will determine if development of autoimmunity coincides with compromised thymic expression of antigens. The time-course of serum CRP expression, development of the anti-CRP auto-antibody response, and T-cell responsiveness to human CRP will be determined for CRPtg/BW mice. Thymic expression of human CRP will be induced experimentally in aged CRPtg/BW mice to determine if this delays the anti-CRP response. These studies provide a unique opportunity to document the spontaneous loss of tolerance to a peripheral self-antigen normally tolerated via intrathymic expression. Inadequate levels of expression of tissue-specific genes in the thymus, causing impaired self tolerance, might be a common mechanism of disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR020614-24
Application #
6413208
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
2001-01-01
Project End
2002-12-31
Budget Start
Budget End
Support Year
24
Fiscal Year
2001
Total Cost
$116,317
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68

Showing the most recent 10 out of 145 publications